14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ABSI vs IPOD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, IPOD (IPOD) captures the overall head-to-head institutional edge over Absci Corporation (ABSI) on higher Unified Composite conviction (58.0/100 HOLD vs. 41.3/100 SELL) after splitting the core matrix 7–1 (led by Valuation Multiples, Profitability & Quality), while ABSI wins 3–2 across the 6-pillar growth and valuation breakdown. ABSI trades at $7.47 (N/M Forward P/E, -9108.3% operating margin) versus IPOD at $10.42 (N/M Forward P/E, 0.0% operating margin).
Growth vs. Quality Trade-Off: IPOD earns the overall head-to-head edge with a stronger Unified Composite Score (58.0/100 HOLD vs. ABSI 41.3/100 SELL) and 0.00β · 2% Vol risk profile, whereas ABSI leads top-line expansion (-19.6% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.
Technical & Structure Timing Caution: ABSI is currently in a Breakdown options structure phase (RSI 38.8); meanwhile IPOD trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABSI vs IPOD. Trailing 12-month operating profitability (ABSI -9108.3% vs IPOD 0.0%) and valuation multiples (ABSI N/M vs IPOD N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Shell Companies value chain with $210.0M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ABSI vs IPOD Key Questions & Quantitative Answers
As of Nov 16, 2026, IPOD (IPOD) captures the overall head-to-head institutional edge over Absci Corporation (ABSI) on higher Unified Composite conviction (58.0/100 HOLD vs. 41.3/100 SELL) after splitting the core matrix 7–1 (led by Valuation Multiples, Profitability & Quality), while ABSI wins 3–2 across the 6-pillar growth and valuation breakdown. ABSI trades at $7.47 (N/M Forward P/E, -9108.3% operating margin) versus IPOD at $10.42 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: IPOD earns the overall head-to-head edge with a stronger Unified Composite Score (58.0/100 HOLD vs. ABSI 41.3/100 SELL) and 0.00β · 2% Vol risk profile, whereas ABSI leads top-line expansion (-19.6% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ABSI is currently in a Breakdown options structure phase (RSI 38.8); meanwhile IPOD trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI N/A). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ABSI leads the Growth & Scale pillar: ABSI posts -19.6% YoY revenue growth and +0.0% YoY earnings growth on $1.5M TTM revenue (N/A gross margin, -9108.3% operating margin), compared with IPOD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ABSI generates $1.5M in USD-normalized revenue versus N/A for IPOD. In operating R&D and SG&A reinvestment, ABSI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for IPOD.
IPOD screens cheaper on headline valuation multiples. ABSI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas IPOD trades at N/M Forward P/E, 39.9x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABSI (-58.6% ROE) versus IPOD (0.0% ROE) capital efficiency.
In options market volatility and institutional positioning, ABSI carries 169.1% implied volatility (15th %ile, Compressed (<25th %ile)), a 0.57x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (3.34β · 128% Vol realized risk). By comparison, IPOD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.00β · 2% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.